At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAZE Maze Therapeutics
Trading 07-13 10:22:26 EDT
29.54
-1.03
-3.37%
High30.37Low29.46Vol130.13K
Open30.04D1 Closing30.57Amplitude2.96%
Mkt Cap1.63BTradable Cap1.31BTotal Shares55.25M
T/O3.90MT/O Rate0.29%Tradable Shares44.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million
Reuters  ·  07-03
Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million
Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares
Reuters  ·  07-02
Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares
Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares
Reuters  ·  06-25
Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
TIPRANKS  ·  06-22
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
TIPRANKS  ·  06-11
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting
Reuters  ·  06-11
Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting
Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83
Reuters  ·  06-04
Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83
Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47
Reuters  ·  06-04
Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47
Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline
Reuters  ·  06-03
Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬
Reuters  ·  06-03
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬
Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45
Reuters  ·  05-28
Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewswire  ·  05-27
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
TIPRANKS  ·  05-23
J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
TIPRANKS  ·  05-23
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
Maze Therapeutics SVP Finance Amy Bachrodt resigns, effective June 1
Reuters  ·  05-23
Maze Therapeutics SVP Finance Amy Bachrodt resigns, effective June 1
Maze CEO Jason Coloma disposes 1,938 Maze Therapeutics shares worth $50,388
Reuters  ·  05-19
Maze CEO Jason Coloma disposes 1,938 Maze Therapeutics shares worth $50,388
Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354
Reuters  ·  05-19
Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354
LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TIPRANKS  ·  05-16
LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)
Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)
TIPRANKS  ·  05-14
Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)
Maze Therapeutics (MAZE) Q1 Loss Of US$24.2 Million Reinforces Bearish Earnings Narratives
Simply Wall St.  ·  05-14
Maze Therapeutics (MAZE) Q1 Loss Of US$24.2 Million Reinforces Bearish Earnings Narratives

Introduction

Company Name.
Maze Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--